106 related articles for article (PubMed ID: 32162720)
1. Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.
Wei R; Thanindratarn P; Dean DC; Hornicek FJ; Guo W; Duan Z
J Orthop Res; 2020 Sep; 38(9):1952-1964. PubMed ID: 32162720
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Ma H; Seebacher NA; Hornicek FJ; Duan Z
EBioMedicine; 2019 Jan; 39():182-193. PubMed ID: 30579871
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study.
Wei R; Dean DC; Thanindratarn P; Hornicek FJ; Guo W; Duan Z
Front Oncol; 2020; 10():596330. PubMed ID: 33282745
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous expression and biological function of ubiquitin carboxy-terminal hydrolase-L1 in osteosarcoma.
Zheng S; Qiao G; Min D; Zhang Z; Lin F; Yang Q; Feng T; Tang L; Sun Y; Zhao H; Li H; Yu W; Yang Y; Shen Z; Yao Y
Cancer Lett; 2015 Apr; 359(1):36-46. PubMed ID: 25578779
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma.
Cui J; Dean D; Wei R; Hornicek FJ; Ulmert D; Duan Z
J Orthop Res; 2020 Nov; 38(11):2362-2372. PubMed ID: 32902907
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.
Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J
Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119
[TBL] [Abstract][Full Text] [Related]
7. Expression and Clinical Significance of High-Mobility Group AT-hook 2 (HMGA2) in Osteosarcoma.
Cui J; Dean D; Hornicek FJ; Yi G; Duan Z
Orthop Surg; 2022 May; 14(5):955-966. PubMed ID: 35388973
[TBL] [Abstract][Full Text] [Related]
8. Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study.
Lundgren C; Ahlin C; Holmberg L; Amini RM; Fjällskog ML; Blomqvist C
Acta Oncol; 2015 Apr; 54(4):538-44. PubMed ID: 25327158
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Ma H; Dean DC; Wei R; Hornicek FJ; Duan Z
Ther Adv Musculoskelet Dis; 2021; 13():1759720X21995069. PubMed ID: 34104229
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
Yang L; Fang D; Chen H; Lu Y; Dong Z; Ding HF; Jing Q; Su SB; Huang S
Oncotarget; 2015 Aug; 6(25):20801-12. PubMed ID: 26204491
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma.
Liu Z; Zhang G; Zhao C; Li J
Med Sci Monit; 2018 Jul; 24():5216-5224. PubMed ID: 30052620
[TBL] [Abstract][Full Text] [Related]
12. Cyclin E1 is amplified and overexpressed in osteosarcoma.
Lockwood WW; Stack D; Morris T; Grehan D; O'Keane C; Stewart GL; Cumiskey J; Lam WL; Squire JA; Thomas DM; O'Sullivan MJ
J Mol Diagn; 2011 May; 13(3):289-96. PubMed ID: 21458381
[TBL] [Abstract][Full Text] [Related]
13. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
15. FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma.
Li Z; Xiao J; Hu K; Wang G; Li M; Zhang J; Cheng G
Int J Mol Sci; 2015 Jan; 16(2):2294-306. PubMed ID: 25622249
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between AKAP95, cyclin E1, cyclin D1, and clinicopathological parameters in lung cancer tissue].
Hu SX; Kong XY; Yuan YY; Teng BG; Zhi XH; Zhuang WX; Yu XY; Liu WZ; Zhang YX
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2013 Dec; 31(12):890-4. PubMed ID: 24370359
[TBL] [Abstract][Full Text] [Related]
17. PP2A-B55β antagonizes cyclin E1 proteolysis and promotes its dysregulation in cancer.
Tan Y; Sun D; Jiang W; Klotz-Noack K; Vashisht AA; Wohlschlegel J; Widschwendter M; Spruck C
Cancer Res; 2014 Apr; 74(7):2006-14. PubMed ID: 24509904
[TBL] [Abstract][Full Text] [Related]
18. CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma.
Ma C; Nie XG; Wang YL; Liu XH; Liang X; Zhou QL; Wu DP
Mol Med Rep; 2019 May; 19(5):4205-4212. PubMed ID: 30942427
[TBL] [Abstract][Full Text] [Related]
19. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.
Wang Z; Tan M; Chen G; Li Z; Lu X
IUBMB Life; 2017 Nov; 69(11):867-876. PubMed ID: 28960757
[TBL] [Abstract][Full Text] [Related]
20. T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Thanindratarn P; Wei R; Dean DC; Singh A; Federman N; Nelson SD; Hornicek FJ; Duan Z
Mol Oncol; 2021 Dec; 15(12):3721-3737. PubMed ID: 34115928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
